Lu Kang Pharmaceutical announced that the company participated in the 12th batch of centralized procurement bidding for national drugs. The product (vancomycin hydrochloride for injection) plans to be selected for this centralized procurement. The procurement period starts from the date of implementation of the selection results to December 31, 2029. The product's 2025 sales revenue was 5.447,800 yuan, accounting for 0.09% of the company's 2025 revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.